We’re reading about Zantac lawsuits, Neurocrine schizophrenia pill

Hello everyone. How are you today? We are in high spirits, especially as the middle of the week is approaching. After all, we have come this far and are determined to push ourselves for a few more days. Why not? The other things we can do, at least the ones we can identify, are not so appealing. There is no better way to fly time than to keep busy. Grab a stimulating cup and get started. For those of you who are tracking your habits, today’s flavor is pumpkin spice. Well, it’s time to get busy. So grab your cup and savor the interesting items we have collected below. Have a great day. Stay in touch. …

The Delaware Supreme Court has agreed to hear an appeal by GSK and other drug companies seeking to end more than 70,000 lawsuits alleging that the discontinued heartburn drug Zantac caused cancer., Reuters GSK, Pfizer, Sanofi and Boehringer Ingelheim are asking the court to overturn a lower court judge’s order that allowed plaintiffs in the lawsuits to present expert testimony about the cancer link, but the companies argue that the link is not supported by sound scientific methodology. Without that testimony, the lawsuits cannot proceed. The pharmaceutical companies won a major victory in 2022 when a federal judge in Florida rejected plaintiffs’ expert testimony in about 50,000 lawsuits because they did not use reliable scientific methodology. Some of the Florida lawsuits are on appeal, and most of the remaining lawsuits are in Delaware.

Neurocrine Biosciences reported that the lowest dose of an experimental schizophrenia drug reduced patient-reported psychosis in a mid-term study, but higher doses of the drug tested had no effect.The company said the findings support the drug’s progression into a Phase 3 study next year, STAT reported. Investors took the conflicting data with more concern, with Neurocrine’s shares falling 18% at the start of trading. The drug belongs to an emerging class of neuropsychiatric drugs that target muscarinic receptors in the brain. This type of drug has been attracting a lot of attention due to the acquisitions of Karuna Therapeutics ($14 billion) and Cerebelle Therapeutics ($8.7 billion) by Bristol-Myers Squibb and AbbVie, respectively.